olverembatinib
ascentage pharmaceuticals,innovent biologics
['cml', 'olverembatinib']
olverembatinib is efficacious and well tolerated in tyrosine kinase inhibitor-resistant cml-cp and cml-ap patients with a bcr-abl1 t315i mutation. #bcsm #ash22 
Oncology news and insights from leading researchers and cancer centers.